Nasdaq IPOs

Virios Therapeutics, a Phase 2 biotech developing novel antiviral therapies for fibromyalgia and other diseases, announced terms for its IPO on Friday. The Alpharetta, GA-based company plans to raise $30 million by offering 3 million shares at a price range of $9 to $11. At the m

Hygo Energy Transition, which provides integrated downstream liquefied natural gas solutions in Brazil, postponed its IPO on Friday. It had filed to raise $450 million by offering 23.1 million shares at a price range of $18 to $21. The postponement follows news that Hygo's CEO,&n

Amesite, which provides an AI-driven platform for developing online learning products, raised $15 million by offering 3 million shares at $5, within the range of $4.50 to $5.50. The company offered 0.1 million fewer shares than anticipated. Amesite plans to list on the Nasdaq und

VIA optronics, a German provider of sunlight readable, ultrathin display and touch solutions, raised $94 million by offering 6.3 million ADSs at $15, the low end of the range of $15 to $17. The company's commercial partner, Corning, has agreed to purchase 1.4 million ADSs at

FinTech Acquisition IV, the fifth blank check company formed by management of The Bancorp to acquire a fintech business, raised $200 million by offering 20 million units at $10. Each unit consists of one share of common stock and one-third of a warrant, exercisable at $11.50. The

Greenwich LifeSciences, a Phase 3 biotech developing immunotherapies for breast cancer, raised $7 million by offering 1.3 million shares (100% primary) at $5.75, the low end of the downwardly revised range of $5.75 to $6.75. The company originally planned to offer 2.7 million sha

Graybug Vision, a Phase 2 biotech developing long-acting formulations of drugs for ocular diseases, raised $90 million by offering 5.6 million shares at $16, the midpoint of the $15 to $17 range. The company originally filed to sell 4.7 million shares, before upsizing the offerin

PMV Pharmaceuticals, an early stage biotech developing targeted therapies for cancer, raised $212 million by offering 11.8 million shares at $18, the high end of the range of $16 to $18. The Cranbury, NJ-based company plans to list on the Nasdaq under the symbol PMVP. Goldman Sa

Prelude Therapeutics, a Phase 1 biotech developing PRMT5 inhibitors for difficult to treat cancers, raised $158 million by offering 8.3 million shares at $19, the high end of the range of $17 to $19. The Wilmington, DE-based company plans to list on the Nasdaq under the symbol P

Vector Acquisition, a blank check company formed by Vector Capital targeting the tech industry, raised $300 million by offering 30 million shares at $10. Each unit consists of one share of common stock and one-third of a warrant, exercisable at $11.50. The company is led by CEO a

Opthea, an Austrialian Phase 3 biotech developing therapies for wet AMD, filed on Thursday with the SEC to raise up to $150 million in an initial public offering. The South Yarra, Australia-based company is currently developing a novel therapy for the treatment of highly prevalen

Opthea, an Austrialian Phase 3 biotech developing therapies for wet AMD, filed on Thursday with the SEC to raise up to $150 million in an initial public offering. The South Yarra, Australia-based company is currently developing a novel therapy for the treatment of highly prevalen

Snowflake (NYSE: SNOW), which provides a cloud-based data warehousing platform, raised $3.4 billion by offering 28 million shares at $120. At pricing, the company commanded a market value of $42.3 billion and qualifies for inclusion in the Renaissance IPO ETF effective Wednesday,

Snowflake (NYSE: SNOW), which provides a cloud-based data warehousing platform, raised $3.4 billion by offering 28 million shares at $120. At pricing, the company commanded a market value of $42.3 billion and qualifies for inclusion in the Renaissance IPO ETF effective Wednesday,

Pulmonx, which makes minimally invasive medical devices for emphysema, announced terms for its IPO on Thursday. The company previously filed to raise $86 million in February 2020 but withdrew the following May after raising $66 million privately. The Redwood City, CA-based compan

Pulmonx, which makes minimally invasive medical devices for emphysema, announced terms for its IPO on Thursday. The company previously filed to raise $86 million in February 2020 but withdrew the following May after raising $66 million privately. The Redwood City, CA-based compan

PMV Pharmaceuticals, a early stage biotech developing targeted therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The Cranbury, NJ-based company now plans to raise $200 million by offering 11.8 million shares at a price range of $16 to $18. The

PMV Pharmaceuticals, a early stage biotech developing targeted therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The Cranbury, NJ-based company now plans to raise $200 million by offering 11.8 million shares at a price range of $16 to $18. The

Immunome, a preclinical biotech developing antibody therapies for cancer and infectious diseases, announced terms for its IPO on Thursday. The Exton, PA-based company plans to raise $30 million by offering 2.5 million shares at a price range of $11 to $13. Insiders intend to buy

Immunome, a preclinical biotech developing antibody therapies for cancer and infectious diseases, announced terms for its IPO on Thursday. The Exton, PA-based company plans to raise $30 million by offering 2.5 million shares at a price range of $11 to $13. Insiders intend to buy